Hungary's national cancer institute, home to the national cancer registry and a leading breast brachytherapy programme.
The National Institute of Oncology in Budapest, founded in 1936, is Hungary's national cancer hospital and research institute and the seat of the Hungarian National Cancer Registry. Under Csaba Polgár, a radiation oncologist known for accelerated partial breast irradiation and the GEC-ESTRO breast brachytherapy trials, the institute coordinates the national cancer control programme and the National Tumour Biology Laboratory. It provides surgical, medical and radiation oncology, haematology, nuclear medicine and pathology for the whole country, hosts a molecular tumour board and an increasing number of international trials, and is OECI-accredited. It collaborates closely with Semmelweis University and the Central and Eastern European oncology groups.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to National Institute of Oncology, including child institutions. 378 works · 3,070 citations · 80% open access · 17% clinical trials · 2% reviews.
Shares Brachytherapy, Most of the world has almost no cancer care, Comprehensive genomic profiling, Head and neck squamous cell carcinoma.
Shares National Korányi Institute for Pulmonology, Organisation of European Cancer Institutes.
Shares Brachytherapy, Organisation of European Cancer Institutes, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares Brachytherapy, Most of the world has almost no cancer care, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares Brachytherapy, Most of the world has almost no cancer care, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares Brachytherapy, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
Shares Brachytherapy, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
Shares Brachytherapy, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.